Understanding how progesterone receptor signaling affects estrogen-positive breast cancer
Official title: Progesterone Receptor (PR) Signaling Cross Talk Drives ER+ Breast Cancer
Funded at University of Minnesota · NIH-10774285 · Data updated 2026-11-12
This study is looking at how different types of progesterone receptors affect the growth of estrogen-positive breast cancer, especially in cases where common treatments like tamoxifen aren't working, to find new ways to help patients with recurring breast cancer feel better and respond to treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project start | February 13, 2020 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $571,826 |
| NIH project number | 5R01CA229697-05 |
| Project ID | NIH-10774285 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with estrogen-positive breast cancer, especially those who have experienced recurrence or resistance to standard treatments.
✕Less likely to help
Patients with other types of breast cancer or those who have not been diagnosed with estrogen-positive breast cancer may not benefit from this research.
What this research studies
This research investigates the role of progesterone receptors in estrogen-positive breast cancer, particularly how their signaling interactions can influence cancer growth and treatment resistance. The study focuses on the different isoforms of progesterone receptors and their effects on cancer cell behavior, especially in cases where traditional therapies like tamoxifen fail. By examining the mechanisms behind these interactions, the research aims to identify new therapeutic targets that could improve treatment outcomes for patients with recurrent breast cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for estrogen-positive breast cancer, particularly for patients who experience recurrence after initial therapy.
How similar studies have gone: Previous research has shown promising results in understanding the role of progesterone receptors in breast cancer, suggesting that this approach could lead to significant advancements in treatment.
Where this research is happening
-
University of Minnesota
Minneapolis, United States Active
Researchers
- Principal investigator: Lange, Carol a — University of Minnesota
- Study coordinator: Lange, Carol a
Related research
Other NIH-funded projects on the same topics.
-
ER+ Breast Cancer Bone Metastasis in a Real Body Environment
This grant aims to understand why estrogen receptor alpha–positive breast cancer often spreads to bone and how the bone environment and immune system affect treatment resistance.
-
Targeting RAGE to fight obesity-related ER+ breast cancer and its drug resistance
A scientist team will explore how obesity-related inflammation involving RAGE and estrone interacts with ER+ breast cancer to drive growth and spread, aiming to find strategies to overcome therapy resistance.
-
Understanding estrogen signals in bone to stop ER+ breast cancer spread
This NIH grant aims to uncover how estrogen signals inside bone help ER-positive breast cancer cells grow and spread, with the goal of finding better ways to prevent bone metastasis.
-
Progesterone Receptor Signaling and Dormancy in ER+ Breast Cancer
Researchers are studying how hormone signals in ER+/PR+ breast cancer influence cancer cell dormancy and later recurrence.
-
Heavy Metals and Breast Cancer Treatment Resistance
This project explores how exposure to heavy metals might make ER+ breast cancer harder to treat and how we might overcome this challenge.
-
Turning ER-positive breast cancer into a viral target for immune attack
This project aims to wake up viral-like bits inside ER-positive breast cancer cells so the immune system can spot and attack them.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.